BeiGene
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, BeiGene sits in the top decile of US sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count).
BeiGene: 65 sponsored US clinical trials, 9 recruiting.
BeiGene sponsors 65 registered US clinical trials on ClinicalTrials.gov, 9 of them currently recruiting, and 37 completed. 12 of these trials are in Phase 3-4 (later-stage) and 52 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 7 trials.
Top-decile sponsor footprint
BeiGene ranks in the top decile of sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
37 of 44 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
65 total, page 2 of 2
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
NCT03427814
A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects
NCT03561298
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
NCT03465059
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
NCT03430843
A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
NCT03432884
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
NCT03412773
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
NCT03332017
Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects
NCT03301181
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03150810
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males
NCT04163783
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
NCT03053440
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
NCT02660034
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
NCT02569476
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
NCT02407990
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
NCT02343120
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 40 |
| Phase 2 | 12 |
| Phase 3 | 12 |
Therapeutic Areas
What is open in the BeiGene pipeline
9 recruiting of 65 indexed (14% open); 37 completed (57%).
Phase mix: 12 late (III/IV) vs 52 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
BeiGene: open-pipeline peers nationwide
Peers matched on 65 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
BeiGene sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 65 trials (± recruiting share)
- Glaxo Wellcome · 65 trials · 0% recruiting
- LEO Pharma · 65 trials · 5% recruiting
- Neurocrine Biosciences · 65 trials · 18% recruiting
- Women and Infants Hospital of Rhode Island · 65 trials · 22% recruiting
Sponsors near 14% open enrollment (± trial volume)
- University of Cincinnati · 14% recruiting · 245 trials
- Milton S. Hershey Medical Center · 14% recruiting · 396 trials
- Virginia Commonwealth University · 14% recruiting · 558 trials
- Lindenwood University · 14% recruiting · 29 trials
Related
What to do with this BeiGene page
65 registered trials is a research-attention snapshot, not an endorsement of BeiGene or any single study.
- 9 of BeiGene's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition BeiGene studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
BeiGene pipeline card: 65 registered trials from official public datasets.Report a data error.